The genomics testing company has swung wildly in value over the past year. Here's the real growth story underneath the volatility — and the risk that comes with it.

GeneDx Holdings (NASDAQ: WGS) has been one of the more volatile names on NASDAQ this year, with its stock swinging between roughly $32 and $171 over a 52-week span and its market cap moving between under $2 billion and well over $4 billion depending on the week. Underneath that volatility is a genuinely fast-growing genomics testing business — and a valuation that already prices in a lot of that growth.

What the company actually does

GeneDx provides genetic testing focused on rare and complex pediatric diseases, built around whole exome and whole genome sequencing, alongside a data and AI platform used for interpreting sequencing results. Its full-year 2026 guidance calls for revenue of $475 million to $490 million, with exome and genome testing volume expected to grow at least 30% and revenue from that segment growing at least 20%, alongside adjusted gross margins projected at 70% or better.

The valuation question

Those growth numbers are real, but they come at a steep price relative to current earnings. The stock has traded at a trailing price-to-earnings ratio in the thousands at various points this year, reflecting the fact that the company is still barely profitable, if at all, on a net income basis — investors are pricing in future profitability rather than current results. Price-to-sales multiples in the 10-to-12 range are also well above what a typical diagnostics company commands, which is standard for a high-growth story but leaves little room for a guidance miss.

Short interest has also been elevated, with roughly 4 to 5 days of average volume needed to cover outstanding short positions in recent data — a sign that a meaningful share of the market is betting the current valuation doesn't hold, even as the underlying volume growth continues.

The honest takeaway

GeneDx is a real growth business in a genuinely expanding market — genetic testing volumes across the industry have been climbing for years, and the company's guidance suggests that continues. Whether the stock is a good entry point at any given price depends entirely on whether that growth rate holds up quarter after quarter, since the current valuation leaves very little margin for disappointment. That's a fundamentally different question than a market-cap prediction, and it's the one actually worth asking before taking a position.